LPCN · Lipocine Inc.
$2.11
+0.05 (+2.43%)
At close · Aug 14
Market Cap
$17.40M
Shares
8.24M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$2.11
Open$2.10
Day$2.07–2.18
52W close$1.94–11.26
Avg vol 30d38K
Short int111K · 1.3% float · 3.6d
Short vol24%
DataMay 2023–Aug 2026
Filing10-Q · Aug 4
Raw chart and full-history price indicators begin at the captured split on May 12, 2023; bars on opposite sides are not compared.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 4, 2026
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 14.3 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−54%
below
Price vs 50-day avg
−6%
below
RSI (14)
43
neutral
MACD trend
Positive
52-week position
2%
near low
Momentum
relative strength
1-month return
−5%
trailing
6-month return
−78%
trailing
YTD return
−74%
this year
Relative strength
−92%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $2 › 200d $5 — 200d above 50d
Institutional flow
Distributing
-26% holders QoQ · +4 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
1.35% of float · ▼ -9.8% MoM · 3.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
35 holders — mid 3-yr range
Squeeze score
50
elevated · 0–100
Fundamentals
Revenue growth
−82%
Y/Y
EPS growth
+46%
Y/Y
Free cash flow
$-9.9M
Balance sheet
$637.9K
net cash
Quant / Vol
risk profile
Volatility
108%
annualized · 1-yr
Max drawdown
−83%
past year
ATR
5.9%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−54%
Bearish
Price vs 50-day avg
−6%
Bearish
RSI (14)
43
Neutral
MACD trend
Positive
Bullish
52-week position
2%
Bearish
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $2 › 200d $5 — 200d above 50d
Institutional flow
Distributing
-26% holders QoQ · +4 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
1.35% of float · ▼ -9.8% MoM · 3.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
35 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $2
Now $2 · 2%
Range high $11
vs 200-day avg -54%
vs 50-day avg -6%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
LPCN
this stock
Lipocine Inc.
|
$17.40M | -73.7% | -82.3% | — | 1.3% |
|
ONC
BeOne Medicines Ltd.
|
$513.62B | +14.4% | +22179.2% | 789.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$128.19B | +11.6% | +46.2% | 29.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$82.72B | +4.1% | +20.8% | 19.9 | 3.3% |
|
ARGX
Argenx SE
|
$52.94B | +1.2% | — | — | 2.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
Raw-price comparisons begin at the captured split on May 12, 2023; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| LPCN | -0.9% | -5.4% | -77.8% | -0.5% | -73.7% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | -1.3% | -9.8% | -91.6% | -4.4% | -87.6% |
Key facts
CIK
1535955
CUSIP
53630X203
13F (30d)
35 filings
34 filers
Visit website
Investor relations